Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205881 | 0.84 | TP53 (0.74) | TP53MAPTNPSR1CXCR3ALDH1A1 | |
| SCHEMBL3193215 | 0.79 | TP53 (0.60) | TP53MAPTMAPK1NPSR1OPRM1 | |
| SCHEMBL2494637 | 0.78 | TP53 (0.70) | TP53MAPTMAPK1NPSR1OPRM1 | |
| SCHEMBL2495808 | 0.77 | MAPT (0.61) | TP53MAPTMAPK1NPSR1OPRM1 | |
| SCHEMBL3207181 | 0.76 | TP53 (0.66) | TP53MAPTMAPK1NPSR1OPRM1 | |
| SCHEMBL2497655 | 0.76 | LMNA (0.79) | MAPTNPSR1CXCR3ALDH1A1TDP1 | |
| SCHEMBL2495408 | 0.75 | TP53 (0.67) | TP53MAPTMAPK1NPSR1CXCR3 | |
| SCHEMBL27976211 | 0.75 | TDP1 (0.63) | NPSR1ALDH1A1TDP1POLB | |
| SCHEMBL3194234 | 0.75 | LMNA (0.65) | TP53MAPTMAPK1NPSR1OPRM1 | |
| SCHEMBL2496126 | 0.75 | CXCR3 (0.77) | TP53MAPTNPSR1CXCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035951-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2041096-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS | NeuroSearch AS (DK) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003752-A1 | 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035951-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN2, KCNN1, KCNN3 | TP53 4533/4885MAPT 2021/4885MAPK1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.